Article Text

PDF
Prescribing dronedarone for paroxysmal atrial fibrillation: how is it done across the UK and is it safe?
  1. Eron Yones,
  2. Jennifer Mullan,
  3. Andrew Horwood,
  4. Nicola Connell,
  5. Sarah Odams,
  6. Jean Maloney,
  7. Andreas L Kyriacou,
  8. Jonathan Sahu,
  9. Justin M Lee,
  10. Nicholas F Kelland
  1. Department of Cardiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust, South Yorkshire, UK
  1. Correspondence to Dr Eron Yones, Department of Cardiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust, South Yorkshire S5 7AU, UK ; eronyones{at}gmail.com

Abstract

Dronedarone, a useful treatment for paroxysmal atrial fibrillation, is often only prescribed in secondary care. To support a protocol shared between primary and secondary care, dronedarone use was audited in our centre and prescribing practices across UK secondary care centres were reviewed. From 2010 to 2015, a total of 181 patients were started on dronedarone. There were no deaths or serious adverse events. Median cessation time due to adverse effects was 52 days and 88% stopped dronedarone within 6 months. Of 17 local prescribing protocols across the UK, 12 involved shared care and 5 purely secondary care follow-up. In our review, dronedarone was safe and well tolerated. The use of shared care protocols is well established in other UK centres. The development of a local shared care protocol between primary and secondary care is feasible with existing systems in place to support its introduction.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.